




BMJ Open Effect of nutritional supplementation on bone mineral density in children with sickle cell disease: protocol for an open-label, randomised controlled clinical trial

Mohamed Condé,¹ Eric Lespessailles ,² Mathilde Wanneveich,³ Delphine Allemadou,⁴ Thierry Boulain ,⁵ Georges Dimitrov ,^{6,7}

To cite: Condé M, Lespessailles E, Wanneveich M, *et al.* Effect of nutritional supplementation on bone mineral density in children with sickle cell disease: protocol for an open-label, randomised controlled clinical trial. *BMJ Open* 2024;**14**:e080235. doi:10.1136/bmjopen-2023-080235

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2023-080235>).

Received 24 September 2023
Accepted 16 March 2024



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Georges Dimitrov;
georges.dimitrov@chr-orleans.fr

ABSTRACT

Introduction Children with sickle cell disease show a significant decrease in bone mineral density, an increase in resting energy expenditure of more than 15%, a decrease in fat and lean mass as well as a significant increase in protein turnover, particularly in bone tissue. This study aims to evaluate the effectiveness of an increase in food intake on bone mineral density and the clinical and biological complications of paediatric sickle cell disease.

Methods and analysis The study is designed as an open-label randomised controlled clinical trial conducted in the Paediatrics Unit of the Orléans University Hospital Centre. Participants aged 3–16 years will be randomly divided into two groups: the intervention group will receive oral nutritional supplements (pharmacological nutritional hypercaloric products) while the control group will receive age-appropriate and gender-appropriate nutritional intake during 12 months. Total body less head bone mineral density will be measured at the beginning and the end of the trial. A rigorous nutritional follow-up by weekly 24 hours recall dietary assessment and planned contacts every 6 weeks will be carried out throughout the study. A school absenteeism questionnaire, intended to reflect the patient's school productivity, will be completed by participants and parents every 3 months. Blood samples of each patient of both groups will be stocked at the beginning and at the end of the trial, for future biological trial. Clinical and biological complications will be regularly monitored.

Ethics and dissemination The protocol has been approved by the French ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre-Mer 2, Toulouse; approval no: 2-20-092 id9534). Children and their parents will give informed consent to participate in the study before taking part. Results will be disseminated through peer-reviewed journals or international academic conferences.

Trial registration number NCT04754711.

INTRODUCTION

Sickle cell disease (SCD) is the most prevalent inherited haemoglobinopathy exhibiting an annual incidence estimate of 300 000

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Prospective, interventional, randomised controlled trial on sickle cell anaemia children is performed to evaluate the effect of nutritional supplementation on bone mineral density and disease complications.
- ⇒ Blinding is not applied due to technical logistic reasons to manufacture a genuine placebo.
- ⇒ Compliance in the consumption of the oral nutritional supplements is ensured by specialised dieticians, with previously planned modalities of contacts and meetings with participants.
- ⇒ Stratified statistical analysis of homogeneous groups in terms of age, gender, disease severity is planned.

births.^{1 2} More than half of these cases stem from Africa, with additional occurrences in India, the Mediterranean region and the Middle East.² During the past five decades, SCD has emerged as the predominant rare disease in France, with a patient count surpassing 30 000, half of them living in the Paris area.³ This establishes France as the European nation harbouring the highest number of affected individuals.

SCD results from a point mutation, which involves the substitution of glutamic acid with valine at position 6 on the beta subunit of haemoglobin, leading to the formation of haemoglobin S (HbS).⁴ While homozygous HbSS patients experience symptomatic manifestations, HbAS heterozygotes are asymptomatic carriers. Variant forms of SCD manifest when mutations associated with other defective haemoglobins (C or E) or beta-thalassaemia combine with HbS, resulting in genotypes SC, SE, Sbeta+ or Sbeta0. Among these, the most severe presentations are SS and Sbeta0.⁵ Under hypoxic conditions, HbS undergoes polymerisation, leading to the



formation of fragile 'sickle' red blood cells (RBCs) characterised by a shortened lifespan. These RBCs contribute to microvascular occlusions by triggering an inflammatory cascade, platelet activation, increased adhesion of RBCs to the vascular endothelium and perturbed nitric oxide (NO) metabolism.⁵ For unknown reasons, the bone is the primary target for acute complications in SCD.^{6,7}

The comprehensive spectrum of symptoms encompassing SCD entails acute painful crises called vaso-occlusive crises (VOC), chronic pain, acute and chronic anaemia, infections and multiorgan involvement.² This results in a significant decline in both the quality of life and life expectancy of patients.^{1,2,8} Neonatal screening, penicillin prophylaxis, pneumococcal conjugate vaccination, transfusion exchange programmes and hydroxyurea (since 2017) have improved prognosis in these high-risk patients.⁹ Haematopoietic stem cell transplant is the only curative treatment, strongly limited by the rarity of matched sibling donors.^{10,11}

The rationale of our study is based on the observation that a general follow-up programme¹² lacks explicit nutritional recommendations and systematic monitoring of bone mineral density (BMD) for children with SCD, even in Western countries. However, those patients exhibit:

- ▶ An increased resting energy expenditure of 15%–20% (quantified via indirect calorimetry).^{13–16}
- ▶ Diminished fat and lean mass.^{15,17,18}
- ▶ A marked increase in protein turnover, particularly affecting bone tissue.¹³
- ▶ A frequent decrease in BMD, ranging between 19% and 56%^{17–22} (table 1).
- ▶ A statistically significant association between reduced BMD and lower body mass index (BMI),^{17–22} although not with vitamin D deficiency.

The objective of this study is to assess the impact of increased oral caloric nutritional intake on BMD in children with SCD, over a 12-month period.

METHODS AND ANALYSIS

Design

This is an open-label, investigator-initiated, randomised, controlled, superiority interventional trial conducted within the Paediatrics Unit of the University Hospital Centre of Orléans, France. Our main hypothesis is that increased oral nutritional caloric intake may improve BMD in children with SCD. Seventy paediatric patients are to be randomised in two parallel groups.

Primary objective

This study is designed to assess the impact of additional 20% oral caloric food intake through oral nutritional supplement (ONS) on change of BMD in children with SCD.

Secondary objectives

We also seek to explore the potential influence of this nutritional intervention on various secondary outcomes. These encompass alterations in body composition (fat/lean body mass), changes in growth parameters (height and weight), frequency of complications related to SCD, school absenteeism (online supplemental file 1), cardiac function, brain vasculopathy and routine biological parameters.

An ancillary objective is the establishment of a blood samples collection for future biological research (inflammation, hypoxia, bone metabolism).

Table 1 Decrease of bone mineral density (BMD) in SCD children and adolescent

Publication	Paediatric SCD participants	Healthy control group	DXA site	Gender	Age (years)	Country	Low BMD (<-1SDs)
Meeuwes <i>et al</i> 2013 ²¹	27	None	Lumbar spine (LS)	12 F–15 M	14.9 (7–28)	Brazil	41%
Gupta <i>et al</i> 2010 ²²	28	24	LS, femoral neck (FN)	14 F–14 M	9.7±3.4	Koweit	18% vs 13% on LS; 4% vs 0% on FN (p>0.05)
Chapelon <i>et al</i> 2009 ¹⁹	53	None	LS, FM, whole body excluding skull (WBES)	27 F–26 M	12.8±2.4 (9–19)	France	67% (F) on LS; similar FM, WBES 45% (M) on LS; similar FM, WBES
Fung <i>et al</i> 2008 ¹⁸	46	None	Whole body	23 F–23 M	11 (4 à 19)	USA	32%
Lal <i>et al</i> 2008 ²⁰	25	None	Proximal femur, LS	13 F–12 M	12.8 (10.2–19.8)	USA	56%
Buisson <i>et al</i> 2005 ¹⁷	90	198	Whole body mineral content	44 F–46 M	4 à 19	USA	32%

DXA, dual energy X-ray absorptiometry; F, female; M, male; SCD, sickle cell disease.




Figure 1 Flow chart of the sickle cell disease nutritional intervention project. DXA, dual energy X-ray absorptiometry; ONS, oral nutritional supplements; SAQ, School Absenteeism Questionnaire.

Study setting and time points

The trial is carried out in the University Hospital Centre of Orléans, France. The total study duration is 42 months, including 30 months of recruitment: starting date 23 September 2021, expected end recruitment date 23 March 2024 (initially 18 months was planned but it was subsequently extended for an additional year), and 12 months of follow-up. Two key assessments are scheduled at enrolment and at the end of the follow-up. Minor assessments will be performed every 6 weeks. A 24-hour recall dietary intake will be done once weekly. [Figure 1](#) illustrates the overall study design.

Definitions

- ▶ Severe form of SCD: No paediatric severity score has been formally validated for SCD. We will use the following clinical criteria to define severity (the first two being suggested by Lal *et al*²⁰):
 - Three or more hospitalisations per year in the 5 years prior to inclusion.
 - Two or more transfusions of packed RBCs per year in the 5 years preceding inclusion.
 - A history of acute chest syndrome in the 5 years prior to inclusion.
- ▶ Acute anaemia is defined as a 2g/dL drop in haemoglobin concentration compared with the initial/usual value.
- ▶ Cerebral vasculopathy assessed by transcranial Doppler: time-averaged mean maximum velocity ≥ 170 cm/second in the supraclinoid internal carotid artery and/or middle cerebral artery.²³

Patient and public involvement

The conception of the study was not influenced by patients or other public experiences or preferences. The investigators designed the study and recruited participants solely on the basis of predefined criteria and without any patient or public pressure.

Recruitment, informed consent and study time points

Children, adolescents and their parents will be approached either during a consultation with a paediatrician for routine follow-up of SCD, or during a hospitalisation, whatever the cause. Oral and written information will be given to the patient and his/her parents during this initial contact (online supplemental file 2). They will consider proposal to take part in the trial and ask any questions until the next consultation, during which the patient will be included if he/she consents and his/her parents give written consent. Date and time of randomisation determine the beginning of the intervention period.

Parents of included patients have the right to withdraw their consent and discontinue their participation at any time for any reasons.

Blinding

The decision was made not to pursue a double-blind study due to logistical, time and financial constraints. Additionally, we anticipated technical challenges in manufacturing a genuine placebo for the oral supplement for various reasons (eg, the supplement would unavoidably increase the volume of the food bolus, it would increase the intake of dietary fibres and/or inert materials that could



potentially affect intestinal transit and/or the absorption of micronutrients).

Inclusion criteria

- ▶ Children between 3 and 16 years old.
- ▶ Following SCD genotypes: SS, SC, SE, Sbeta+ and Sbeta0.

Exclusion criteria

- ▶ Children who are overweight: BMI \geq 97th percentile.
- ▶ Children refusing, or for whom one of the two parents refuses the participation in the study.

In the case of siblings, only one child will be selected at random from all the children of the sibling group. The others will receive (free of charge), ONSs, if they so wish and if this is the group assigned to the selected children.

Randomisation

The randomisation by sealed envelopes will be done in two parallel arms by physician and/or nutritionist, with an allocation ratio of 1:1, with permutation blocks, the size of which will be unknown to the investigators. It will be stratified on three variables:

- ▶ Age: \leq or $>$ 8 years old.
- ▶ Gender.
- ▶ Severe or mild form of SCD.

Intervention

Each enrolled and randomised child will undergo key interventions as part of his/her annual routine general check-up conducted in a day hospital setting:

Nutritional assessment by a nutritionist

After randomisation, dietary intake assessment and anthropometric measures for all subjects, paediatric nutritionist will define the daily quantity of ONS to take for each subject of the intervention group. Detailed ONS composition is furnished in online supplemental file 3. ONS (provided to subjects as part of the study) will be distributed every 3 months during consultation, for the following 3 months. Intervention group participants will receive instructions for caloric increase with an ONS on the basis of his/her BMI: for BMI $<$ 50th percentile: increase in intake to reach or surpass the 50th percentile, and an additional 20% caloric intake in the form of ONS; for BMI $>$ 50th and $<$ 97th percentile, an additional 20% caloric intake in the form of ONS. If a child becomes overweight (BMI $>$ 97th) during the study, he/she will be excluded but will be rigorously followed by a dietician and physician until normalisation. The daily quantity of ONS will depend on one hand on the results of the dietary intake carried out beforehand for each patient included, and on the other hand—on the gustative interest of the child for this or that product. The intake of proteins, carbohydrates and lipids will be adapted so that it does not exceed the recommended daily intake.²⁴ The quantity of ONS consumed per day will in no case exceed 400 mL. Nutritionist will explain to patients/parents that the purpose of ONS is not a replacement

of a usual meal but an addition to it in order to reach a caloric increase of 20% over the age-appropriate caloric recommendations. Different aromas and forms of ONS will be proposed, possibility to change ONS during the trial, possibility to contact dietician at any time (email, phone), planned contact with participants every 6 weeks. Moreover, we will collect empty ONS packaging. Nutritionist will assess dietary intake by a 24-hour recall. Evaluation of food intake will be performed 1 day per week in written form. Concerning the six other days of the week parents will be questioned about any changes of food habits of their child. If the child has eaten differently on one or more of the other 6 days of the week, this will be considered in the caloric calculation. During some special periods (holidays, hospitalisations) dietary assessment will be adapted to food intake changes. If illiterate parents, nutritionist will use photographs of the meals and estimate calories using professional nutritional guide such as <https://dietcie.com/wp-content/uploads/2021/02/Guide-des-portions-pdf-comprese.pdf>. Therefore, if necessary, change of caloric intake will be performed each week during the trial.

Nutritional status of subjects of control group will also be assessed by the nutritionist in order to correct, if necessary, caloric food intake to age-appropriate caloric recommendations.

- ▶ Total body less head (TBLH) BMD for all subjects will be measured by two experienced operators in the anterior–posterior direction by dual energy X-ray absorptiometry (DXA) using a Hologic Horizon system (Hologic, Waltham, Massachusetts, USA). As SCD is a chronic condition associated with malnutrition and with muscle deficits, soft tissue measures, that is, lean and fat body mass (%), will also be performed at baseline and at the end of the study. Considering the wide age range of children and adolescents who are to be recruited, the description of the study population in terms of BMD will use BMD values adjusted for individual body height, sex and age as recommended.²⁵
- ▶ School absenteeism questionnaire for all subjects (in number of days, online supplemental file 1), intended to indirectly reflect the patient's school productivity. This will be filled in by the patient him/herself and his/her parents. This questionnaire will be checked for completion at each medical consultation planned at 3-month intervals during the study (figure 1).
- ▶ Collection of blood samples for future research trials for all subjects.

Evaluation and outcomes

The primary outcome is the change in mean TBLH BMD of the two randomised groups (in g/cm^2) during the time frame month 12 (M12)–baseline (first day of inclusion).

The secondary outcomes include:

- ▶ Change in body composition expressed by lean body mass (%), fat mass (%), bone mass, by region of the body and overall, during the time frame M12–baseline.

- ▶ Rate of participants with change of height (cm, percentile according WHO curves)²⁶ and weight (kg, percentile according WHO curves)²⁶ during the time frame month 12–baseline (day 1 of inclusion).
- ▶ Assessment of school absenteeism questionnaire at baseline, months 3, 6, 9 and 12.
- ▶ Frequency of complications of SCD during the study period (M12): VOC, chronic pain, acute anaemia, infections.
- ▶ Presence or not of impaired cardiac function and/or cardiac anatomy related to SCD determined by echocardiography, at baseline and M12.
- ▶ Presence of cerebral vasculopathy assessed by transcranial Doppler at baseline and M12.
- ▶ Value change of haemoglobin F-S-C, lactate-dehydrogenase (LDH) concentration iron and ferritin, serum folate, C reactive protein and 25 OH vitamin D at baseline and month 12.

Sample size

Based on the literature,^{17–22} we hypothesise an increase in BMD in the intervention group corresponding to an effect size of 0.75 (the difference in the mean of BMD between the two groups will be 0.75 times the SD of the total population of the two groups). This reflects a strong effect of ONSs on BMD compared with control group, with a significant difference in the mean of BMD between the two groups. To show such a difference with a power of 80% and an α risk of 5%, the inclusion of 70 patients (35 patients in each group) is necessary if it is estimated that 20% will be lost to follow-up.

General management

The care and follow-up of children will comply with the management usually recommended¹²: (1) Medical consultation with clinical examination every 3 months including anthropometric parameters (weight, height, BMI, growth curve) and classification as prepubescent (girls P1/S1, boys G1/P1 according to Tanner's classification) or pubescent (girls P2–P5/S2–S5, boys G2–G5/P2–P5 according to Tanner's classification); (2) Biological monitoring every 3 months on the same day of the consultation: total haemoglobin, haemoglobin F-S-C, serum LDH, serum iron, ferritin, folate, CRP, vitamin D and (3) Echocardiography and transcranial Doppler every year.

Study safety, monitoring and data management

As this trial is associated with minimal risks according to French Law, we did not plan to set up an independent data safety and monitoring board. No adverse effects have been reported since the beginning of March 2021. Nevertheless, the study can be suspended or prematurely interrupted in case of unexpected serious adverse events, requiring the examination of the evolution of all the patients already included. University Hospital of Orléans reserves the right to interrupt the study at any time if the inclusion objectives are not reached. The investigator can

definitively or temporarily stop the patient's participation for any reason which would better serve the patient's interests, and especially in case of serious adverse effects. In this case, these reasons are collected, assessed and reported.

A paper clinical report form (CRF) will be filled in by the investigators and the nutritionist at each visit or phone call. Clinical study technicians assigned by the sponsor will regularly check the CRFs to ensure that the data are complete and accurate, and that they correspond to the source data.

Data management is performed by the Direction de la Recherche, University Hospital Centre of Orléans. Research assistants regularly monitor collected data to check adherence to protocol and accuracy of collected information.

Statistical analysis

The variation in TBLH BMD between inclusion and 1 year will be compared between the two groups of randomisations by using a linear mixed model. We assumed that patients would have a random intercept. The randomisation group and the stratification variables will be handled as independent variables with a fixed effect. The differences in BMD and its variation between the two groups of randomisations will also be presented for the subgroups used to stratify the population, whether or not there is interaction between strata and treatment. Results will also be presented for different age groups ((3–5), (5–7), (7–9), (9–11), (11–13), (13–16 years)), as well as in prepubescent and pubescent children separately. Finally, the change in TLBH BMD of the two groups of randomisations (and by stratification variables) will also be described (1) using the reference population implemented in the DXA machine and (2) after adjustment of the TLBH BMD value for height-adjusted Z-scores of each category of age and gender.²⁵

The secondary endpoints will be described at the different follow-up times of the study.

Subgroup description will be provided for each stratification variable (age, gender, severity), with appropriate graphic representations. Missing or aberrant data will be replaced by multiple imputation by chained equations (Function 'mice' of the R package 'mice') by generating 50 complete imputed populations; and 'pooled' analyses on these 50 populations.

ETHICS AND DISSEMINATION

Ethics approval

This paediatric study protocol was approved by the institutional review board of Orléans' Hospital, as well as by the French ethics committee (Comité de Protection des Personnes Sud-Ouest et Outre-Mer 2, Toulouse; approval no: 2-20-092 id9534) on 5 November 2020 and was registered in ClinicalTrials.gov (NCT04754711).

The study is conducted in accordance with the current revision of the Declaration of Helsinki, 1996, International

Conference on Harmonisation Note for Guidance on Good Clinical Practice (ICH GCP) and the applicable French regulatory requirements.

Author affiliations

- ¹Paediatrics, Centre Hospitalier Régional d'Orléans, Orléans, France
²Rheumatology, Centre Hospitalier Régional d'Orléans, Orléans, France
³Statistics Department, Centre Hospitalier Régional d'Orléans, Orléans, France
⁴Nutrition Department, Centre Hospitalier Régional d'Orléans, Orléans, France
⁵Medical Intensive Care Unit, Centre Hospitalier Régional d'Orléans, Orléans, France
⁶Paediatrics, Centre Hospitalier Régional d'Orléans, Orléans, France
⁷Paediatric Surgery, Centre Hospitalier Régional d'Orléans, Orléans, France

X Delphine Allemandou @Delphine

Contributors GD, EL and TB designed the study. GD, MC, TB and EL wrote the study protocol. TB determined the sample size. TB and MW planned statistical analysis and data interpretation. GD is the coordinating investigator. MC and DA include patients. All authors reviewed and approved the final version of the manuscript.

Funding The study is funded by the University Hospital Centre of Orléans, France, who did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Disclaimer The funder has no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. None of the companies that manufacture and/or market the Oral Nutritional Supplements herein tested are involved in the study design, data analysis and interpretation or in the drafting of the article.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Consent obtained from parent(s)/guardian(s).

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Eric Lespessailles <http://orcid.org/0000-0003-1009-8518>
 Thierry Boulain <http://orcid.org/0000-0003-4664-3661>
 Georges Dimitrov <http://orcid.org/0009-0006-5852-7624>

REFERENCES

- Piel FB, Hay SI, Gupta S, *et al*. Global burden of sickle cell anaemia in children under five, 2010–2050: Modelling based on demographics. *PLoS Med* 2013;10:e1001484.

- Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: A review. *JAMA* 2022;328:57–68.
- Arlet J-B. Epidemiology of sickle cell disease in France and in the world. *Rev Prat* 2023;73:500–4.
- Ware RE, de Montalembert M, Tshilolo L, *et al*. Sickle cell disease. *Lancet* 2017;390:311–23.
- Kato GJ, Piel FB, Reid CD, *et al*. Sickle cell disease. *Nat Rev Dis Primers* 2018;4:18010.
- Gupta A, Tripathi L, Pandey S, *et al*. Biology of bone Morphogenetic proteins in skeleton disease: Osteonecrosis in sickle cell disease patients. *Curr Protein Pept Sci* 2022;23:264–70.
- Giordano P, Urbano F, Lassandro G, *et al*. Mechanisms of bone impairment in sickle bone disease. *Int J Environ Res Public Health* 2021;18:1832.
- Odame I. Sickle cell disease in children: an update of the evidence in Low- and middle-income settings. *Arch Dis Child* 2023;108:108–14.
- Lee MT, Ogu UO. Sickle cell disease in the new era: advances in drug treatment. *Transfus Apher Sci* 2022;61:S1473-0502(22)00239-7.
- Tanhehco YC, Bhatia M. Hematopoietic stem cell transplantation and cellular therapy in sickle cell disease: where are we now *Curr Opin Hematol* 2019;26:448–52.
- Anurogo D, Yuli Prasetyo Budi N, Thi Ngo M-H, *et al*. Cell and gene therapy for anemia: hematopoietic stem cells and gene editing. *Int J Mol Sci* 2021;22:6275.
- de Montalembert M, Tshilolo L, Allali S. Sickle cell disease: a comprehensive program of care from birth. *Hematology Am Soc Hematol Educ Program* 2019;2019:490–5.
- Buchowski MS, de la Fuente FA, Flakoll PJ, *et al*. Increased bone turnover is associated with protein and energy metabolism in adolescents with sickle cell anemia. *Am J Physiol Endocrinol Metab* 2001;280:E518–27.
- Borel MJ, Buchowski MS, Turner EA, *et al*. Alterations in basal nutrient metabolism increase resting energy expenditure in sickle cell disease. *Am J Physiol* 1998;274:E357–64.
- Barden EM, Zemel BS, Kawchak DA, *et al*. Total and resting energy expenditure in children with sickle cell disease. *J Pediatr* 2000;136:73–9.
- Singhal A, Parker S, Linsell L, *et al*. Energy intake and resting metabolic rate in preschool Jamaican children with homozygous sickle cell disease. *Am J Clin Nutr* 2002;75:1093–7.
- Buisson AM, Kawchak DA, Schall JI, *et al*. Bone area and bone mineral content deficits in children with sickle cell disease. *Pediatrics* 2005;116:943–9.
- Fung EB, Kawchak DA, Zemel BS, *et al*. Markers of bone turnover are associated with growth and development in young subjects with sickle cell anemia. *Pediatr Blood Cancer* 2008;50:620–3.
- Chapelon E, Garabedian M, Brousse V, *et al*. Osteopenia and vitamin D deficiency in children with sickle cell disease. *Eur J Haematol* 2009;83:572–8.
- Lal A, Fung EB, Pakbaz Z, *et al*. Bone mineral density in children with sickle cell anemia. *Pediatr Blood Cancer* 2006;47:901–6.
- Meeuwes M, Souza de Carvalho TF, Cipolotti R, *et al*. Bone mineral density, growth, pubertal development and other parameters in Brazilian children and young adults with sickle cell anaemia. *Trop Med Int Health* 2013;18:1539–46.
- Gupta R, Marouf R, Adekile A. Pattern of bone mineral density in sickle cell disease patients with the high-Hb F phenotype. *Acta Haematol* 2010;123:64–70.
- Hirtz D, Kirkham FJ. Sickle cell disease and stroke. *Pediatr Neurol* 2019;95:34–41.
- National Agency for Health Safety Food Environment and work ANSES. Recommended Nutritional Intakes for the French population, 2001, revised in 2016 and 2021, Available: <https://www.anses.fr/fr/content/publication-des-nouvelles-références-nutritionnelles-en-vitamines-et-minéraux>
- Zemel BS, Kalkwarf HJ, Gilsanz V, *et al*. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. *J Clin Endocrinol Metab* 2011;96:3160–9.
- World Health Organisation. Obesity and overweight, Available: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>

Supplement online 1.**School absenteeism questionnaire**
(To be completed every 3 months)

1. *Are you currently going to school?*

- Yes
- No, due to sickle cell disease (pain, fever, fatigue)
- No, not related to sickle cell disease

2. *If you usually go to school, indicate your class:*

3. *You go to school :*

- full time
- part-time due to sickle cell disease (pain, fever, fatigue)
- part-time not related to sickle cell disease

4. *Have you been absent from school for a total of at least 5 days in the past 3 months?*

- No
- Yes, due to sickle cell disease (pain, fever, fatigue)
- Yes, unrelated to sickle cell disease

5. *If you had been absent from school for at least 5 days in the last 3 months due to sickle cell disease*

(pain, fever, fatigue), is it rather:

- Less than 6 days
- 6 to 10 days
- 10 to 15 days
- 15 to 20 days
- More than 20 days

6. *Have you had homeschooling in the past 12 months?*

- No
- Yes, due to sickle cell disease (pain, fever, fatigue)
- Yes, unrelated to sickle cell disease

INFORMATION LETTER AND CONSENT FORM for PARENTS

Clinical trial

University Hospital Centre of Orléans

Effect of nutritional management of children with sickle cell disease on bone mineral density and body composition

Sir, Madam,

Your child has sickle cell disease, the most common hereditary disease of the red blood cell. Your child's symptoms are linked to hemolysis (rupture of red blood cells) and vaso-occlusion (obstruction of blood vessels). As your doctor has informed you, your child may present with acute painful crises called vasoocclusive crises (VOC), chronic pain, acute and chronic anemia, infections and damage to several organs. It is also shown that osteoporosis (bone transparency) is much more common. A child with sickle cell disease expends more energy, even when resting, compared to a healthy child.

During these complications your child may eat insufficiently.

In the current state of knowledge, doctors do not have reliable recommendations regarding the proper nutrition of children with sickle cell disease.

In these circumstances, we would like to involve your child in a therapeutic nutritional trial.

Before agreeing to participate in this research project, please take the time to read and understand the information that follows. This document explains the purpose of this research project, its procedures, advantages, risks and disadvantages. We invite you

to ask any questions you deem useful to the person presenting this document to you. You can refuse to participate in this study at any time without prejudice.

Purpose of the study:

The main objective of this therapeutic trial will be to check whether an increase in nutritional intake will improve your child's bone mineral density (bone strength) and body composition (muscles).

Our secondary objectives are to verify whether this increase in nutritional intake can be beneficial for growth, complications of sickle cell disease (VOC, chronic pain, acute and chronic anemia, infections), school absenteeism, cardiac function, cerebral vasculopathy and biological parameters for monitoring your child. We also wish to keep blood samples from your child in order to carry out later during a future study dosage of different substances (cytokines of inflammation, markers of oxidative stress and other bio-markers according to updated data from the literature) for the purpose of scientific research to better understand the effect of nutrition on sickle cell disease.

How is this going to happen?

In addition to the usual care and monitoring, if you accept that your child participates in the study, we will draw lots to find out whether your child enters the “*nutritional supplement*” group or the “*control*” group. If your child falls into the “*nutritional supplement*” group, he will receive an oral nutritional supplement increasing his caloric intakes by approximately 20%. He/she will therefore have to consume once or twice a day a high-calorie and balanced nutritional product, of liquid consistency, in quantities of 200 to 400 ml per day for 1 year.

If your child enters the control group, he/she will keep his usual nutritional intake and will not have to change his eating habits.

Whether your child is in one or other of the groups, the following will be carried out:

* Measurements by dual-photon absorptiometry of your child's bone mineral density (bone strength) and body composition (muscles) will be taken 2 times: at inclusion, and 12 months later. This device allows you to measure bone mineral content (BMC), BMD and body composition PAINLESSLY and in 3 minutes. This examination is safe since it delivers irradiation TEN TIMES LOWER THAN THAT OF A PULMONARY X-ray. Thus, the densitometric measurement exposes a maximum to irradiation of 1.92 μ Sv to 6.77 μ Sv.

For comparison, a pelvic scanner exposes at 6000 μ Sv, a lateral incidence x-ray of the lumbar spine at 530 μ Sv, and a mammogram at 450 μ Sv.

These are therefore rates much lower than the annual natural irradiation that we receive in France which is 2 mSv, knowing that we must add 1mSv for every 3000m of altitude. During air transport, average exposure is 2 to 4 μ Sv per hour.

Additionally, there is no evidence of effects on human health below 100 mSv.

* quarterly nutritional monitoring: a dietitian will ask you to specify what your child eats. Depending on your answer, with the doctor's agreement, she will prescribe the oral nutritional supplement (if your child is in the "nutritional supplement" group) that your child will have to drink. She/He will ask you to keep the empty packaging and return it to her. You will also need to keep a food tracking diary to note how much product your child drinks every day. You will see the dietician at the same time as you meet your hospital doctor. You will therefore not have to come back more often than usual, i.e. every 3 months. She/He will telephone you 6 weeks after each consultation to check if your child has difficulty consuming this product.

* In addition, if you agree, we would like to keep samples of 10 ml of your child's blood: on 2 occasions, one at inclusion, and one 12 months later. We wish to

carry out later during a future study dosage of different substances (cytokines of inflammation, markers of oxidative stress and other bio-markers according to updated data from the literature) for the purpose of scientific research to better understand the effect of nutrition on sickle cell disease. These samples will be frozen and stored at -80°C in the Biopathologies Unit of The University Centre Hospital of Orléans.

* The data collected during traditional monitoring of your child's pathology will also be used (medical examinations, imaging, questionnaires, etc.), in an anonymized manner, as part of this research. They can also be used when analyzing the serum library, always in an anonymous manner.

If your child ever becomes overweight during follow-up, we will immediately stop consumption of the Oral Nutritional Supplement. We will set up prolonged medical monitoring by a specialist and dietician with a view to a normal-calorie diet and appropriate physical activity, until your child returns to a normal weight.

If your child receives the oral nutritional supplement, you will need to bring back the empty packaging at each visit, which will allow us to ensure proper consumption of the product.

In addition, you and your child should answer a school absenteeism questionnaire at baseline, then every 3 months.

The planned duration of the study is 1 year, but you will not have to return to the University Hospital Centre of Orléans more frequently than as part of your usual follow-up.

What are the expected benefits?

This study allows your child to benefit from prolonged nutritional monitoring. Likewise, benefits in terms of public health are expected such as improvement in bone strength

and body composition (musculature). Complications of sickle cell disease may be less common and/or less severe if your child's nutritional status is better. All this would allow the optimization of the care of children with sickle cell disease.

What are the risks and constraints?

These examinations are painless, non-invasive and have a low irradiation rate, much lower than those of a traditional x-ray. The dose is 1/10th of that received by a patient undergoing a chest x-ray.

3. Participation in other studies:

The research protocol does not provide for a ban on participating simultaneously in another research study, nor for an exclusion period during which participation in another research study is prohibited.

What are your rights?

Your child's doctor must provide you with all the necessary explanations concerning this research, the purpose of which meets the criteria of public interest. If you wish to remove your child at any time, and whatever the reason, he/she will continue to benefit from medical monitoring and this will in no way affect his/her future monitoring.

As part of this research, computer processing of your child's personal data will be implemented to enable the results of the research to be analyzed with regard to the objective of the latter which has been presented to you.

This processing complies with the regulatory provisions allowing a health establishment to process data for scientific research purposes. The person responsible for this processing is the University Hospital Centre of Orléans, promoter of the research. In accordance with the European Data Protection Regulation, the University

Hospital Centre of Orléans has appointed a data protection delegate who you can contact at the following email address: dpo@chr-orleans.fr.

To this end, medical data concerning your child will be transmitted to the research promoter or to the people or companies acting on his behalf, in France or abroad. This data will be identified by a code and/or your initials. These data may also, under conditions ensuring their confidentiality, be transmitted to French or foreign health authorities and to other entities of the University Hospital Centre of Orléans.

The University Hospital Centre of Orléans, as part of future collaborations, may also transfer this coded data to institutional or industrial scientific teams in France or around the world in order to continue research on the subject or for scientific research purposes in accordance with General Data Protection Regulation (GDPR).

Furthermore, in accordance with the provisions of the law relating to data processing, files and freedoms (law of January 6, 1978 as amended), and European Regulation 2016/679 of April 27, 2016 (GDPR), you have at any time 'a right of access, rectification, portability and limitation of your child's personal data. You can also lodge a complaint with a supervisory authority (CNIL for France). You also have the right to object to the transmission of data covered by professional secrecy that may be used in the context of this research. and to be processed. Exercising this right involves withdrawing your consent to participate in the trial. In this case, the data obtained before it was removed will be used in the research.

During or at the end of the research, you can access directly or through the doctor of your choice to all of your child's medical data in accordance with the provisions of article L1111-7 of the code of public health and the GDPR of the European Union n°2016/679. These rights are exercised with the doctor who follows your child as part

of the research and who knows his or her identity or the Data Protection Officer of the University Hospital Centre of Orléans.

Your child's data will be retained throughout the research. After the end of the research, the data will be archived for a period in accordance with regulatory provisions (minimum 15 years), then destroyed.

In accordance with the public health code and decree n°2017-884 of May 9, 2017,

- o this research obtained a favorable opinion from the Committee for the Protection of People (French ethics committee)

- o The National Agency for the Safety of Medicines and Health Products (ANSM) has been informed of this study.

- o when this research is completed, you will be kept personally informed of the overall results by your doctor as soon as they become available, if you wish.

After reading this information note, do not hesitate to ask your child's doctor any questions you have. After a period of reflection, if you agree to participate in this research, you must sign your consent to participate in this study. A copy of the complete document will be given to you.

CONSENT

(3 copies: 1 for the father, 1 for the mother, 1 for the investigator)

Child's first and last name.....

Mother of the child (or legal representative)

I, the undersigned (last name, first name):

consent:

for my child to participate in the research entitled: "Effect of nutritional management of children with sickle cell disease on bone mineral density and body composition"

for my child to take part in creation of blood-bank

I have read the form and understood the purpose, nature, advantages, risks and disadvantages of the research project. I am satisfied with the explanations, details and answers that the researcher provided me, where applicable, regarding my child's participation in this project.

Date and signature of the mother:

Father of the child (or legal representative):

I the undersigned (last name, first name)

consent:

for my child to participate in the research entitled: "Benefit of nutritional management of children with sickle cell disease on bone mineral density and body composition

for my child to take part in creation of blood-bank

I have read the form and understood the purpose, nature, advantages, risks and disadvantages of the research project. I am satisfied with the explanations, details and answers that the researcher provided me, where applicable, regarding my child's participation in this project.

Date and signature of father:

Date and signature of the investigator:

INFORMATION LETTER AND CONSENT FORM (Children aged 12 to 16 years)

Clinical trial

Effect of nutritional management of children with sickle cell disease on bone mineral density and body composition

Your parents have accepted that you participate in the trial proposed by our doctors in the University Hospital Centre of ORLEANS. This research will be carried out in association with our dietitians.

Take the time to read and understand the information that follows to find out if you too agree to participate.

This document explains the purpose of this research project, its procedures, advantages, risks and disadvantages. We invite you to ask all the necessary questions.

Nature of the study:

The aim of this study will be to check if a good diet can improve your bone strength and musculature (body composition). We also want to see if the problems linked to your illness – pain, fever, fatigue, shortness of breath, school absences – would be less frequent if your diet was higher in calories.

With your agreement, we will keep samples of your blood taken during the usual check-ups for future scientific analyses.

Procedure for participation:

During this study you may be eligible to receive a food supplement (“fortifying milk”), through a random drawing system.

Our dietitians will follow you closely, as will our doctors.



We will keep samples of your blood 2 times - at baseline, and 12 months later in order to analyze your inflammation later.

If you are overweight during follow-up, you will be excluded from the study.

If you receive the oral nutritional supplement, you should not throw it away once drunk, because we want to collect the empty packaging to let us know that you are drinking the product.

The expected duration of the study is 1 year.

Possible benefits, risks or disadvantages related to your participation:

During this study you will benefit from the usual monitoring by your doctor.

In addition, a dietitian will monitor your nutritional status.

Examining your bone density and body composition is not dangerous for your health even if it is carried out twice in 1 year. We will try to do it one day when you consult your hospital doctor.

The samples of your blood taken twice in 1 year will correspond to blood tests that your doctor must carry out anyway. The amount of blood drawn will be small so that you will not be tired.

The benefits of this study are linked to the results (of these examinations and your usual follow-up) which will allow us to know if increasing your diet can improve your bone condition, your musculature, but also the complications of your disease and therefore, your health.

All your personal data will be used anonymously for research.

We thank you for taking the time to read this newsletter. Your collaboration is valuable for carrying out the research.

INFORMATION LETTER AND CONSENT FORM (Children aged 6 to 11 years)

Clinical trial

Effect of nutritional management of children with sickle cell disease on bone mineral density and body composition

Your parents have given us permission for you to participate in research concerning your disease.



We, your doctors, want to know if when you eat better you will feel better.

Do you also agree to participate?

You will regularly see our dietitians who will talk to you about your diet.



The goal of this study is to show a relationship between your diet and the strength of your bones, your muscles, and the problems related to your illness – pain, fatigue, fever, absences from school.

Your participation consists of

- Follow the dietary advice, and eat, if they ask you, a “fortifying milk”



- Allow us to measure the strength of your bones and muscles (by taking a sort of photo using the device below).



- Allow us to preserve and analyze your blood by scientists



All this information, and that concerning you for monitoring your disease, will then be used for the study, without ever naming you.

Your results will remain a secret.

Do you have questions?



Thank you for your participation.

Supplement online 3. Oral Nutritional Supplements information

Product	FRESUBIN® Energy Drink	Fresubin® Jucy	Fortimel® Jucy	Delical® fruit	Fortimel® Energy	Fortimel® Yog	Fortimel® Compact
Energy (Kcal/ml)	1.5	1.5	1.5	1.3	1.5	1.5	2.4
Macronutriments % (g/100ml)							
Proteins	15 (6)	11 (4)	11 (4)	12 (4.1)	16 (6)	16 (5.8)	16 (9.6)
Lipids	35 (5.8)	0 (0)	0 (0)	0 (0)	34 (5.8)	34 (5.8)	35 (9.3)
Carbohydrates	50 (18.4)	89 (33.5)	89 (33.5)	88 (26)	50 (18.4)	49 (18.7)	49 (29.6)
Micronutriments (in 100ml)							
Sodium (mg)	80	6	8.5	15	90	105	96
Potassium (mg)	135	7	9.5	25	159	201	237
Chloride (mg)	100	190	180	55	86	130	85
Calcium (mg)	135	50	25	18.8	91	108	176
Magnesium (mg)	21	1	1.64	17.4	23	34	32.5
Phosphorus (mg)	80	11	12	80	78	108	182
Iron (mg)	2	2.5	2.5	1.7	2.4	2.4	3.8
Zinc (mg)	1.5	1.88	1.8	1.5	1.8	1.5	2.9
Copper (mg)	0.3	0.38	0.34	0.21	0.27	0.27	0.43
Manganese (mg)	0.4	0.5	0.15	-	0.5	0.2	0.84
Iodine (µg)	30	37.5	25	-	20	20	36.3
Molybdenum (µg)	15	18.8	10	-	15	15	24
Chromium (µg)	10	12.5	8	11	10	7.9	16
Fluorine (mg)	0.2	0.25	0.17	-	0.15	0.15	0.18
Selenium (µg)	10	12.5	8.7	10	8.6	8.5	14.7
Vitamin A (µg)	170	150	82	0	123	122	240
Vitamin D (µg)	2	2.5	1.8	2.1	1.1	1	1.8
Vitamin E (mg)	3	3.75	2.3	2.1	1.9	1.9	3
Vitamin K (µg)	16.7	25	10	6.1	8	8.7	13
Vitamin B1 (thiamine) (mg)	0.23	0.3	0.3	0.32	0.23	0.22	0.4
Vitamin B3 (niacin) (mg)	3	1.8	3	2.2	1.3	2.53	2
Vitamin B2 (riboflavin)(mg)	0,32	0.4	0.32	0.3	0.24	0.24	0.4
Vitamin B5 (pantothenic acid) (mg)	1.2	1.5	1	1.3	0.8	0.79	1.3
Vitamin B6 (mg)	0.33	0.43	0.33	0.31	0.26	0.25	0.4
Vitamine B9 (folate)	50	62.5	41.3	35	40	40	64
Vitamin B12 (µg)	0.6	0.75	0.6	0.5	0.32	0.6	0.7
Vitamin C (µg)	15	18.8	19	0	15	15	24
Choline (mg)	26.7	-	68.8	-	55	55	88
Osmolarity (mOsm/l)	400	680	750	800	450	740	790
Form	Liquid milky	Liquid	Liquid	Liquid	Liquid milky	Liquid yogurt	Liquid milky

Presentation	Bottle 200 ml	Bottle 200 ml	Bottle 200 ml	Bottle 200 ml	Bottle 200 ml	Bottle 200 ml	Bottle 125 ml
Aromas (n)	9	5	7	5	4	2	4
Manufacturer / Distributer	<i>Fresenius Kabi France</i> 5, place du Marivel 92316 Sèvres, France	<i>Fresenius Kabi France</i> 5, place du Marivel 92316 Sèvres, France	<i>Nutricia Nutrition Clinique</i> 17-19 rue des deux-gares CS 50149 92565 Rueil-Malmaison CEDEX, France	<i>Lactalis Nutrition Santé</i> Zone d'activités du haut montigné 600 rue Chalonge 35370 Torcé, France	<i>Nutricia Nutrition Clinique</i> 17-19 rue des deux-gares CS 50149 92565 Rueil-Malmaison CEDEX, France	<i>Nutricia Nutrition Clinique</i> 17-19 rue des deux-gares CS 50149 92565 Rueil-Malmaison CEDEX, France	<i>Nutricia Nutrition Clinique</i> 17-19 rue des deux-gares CS 50149 - 92565 Rueil-Malmaison CEDEX, France